Osaka, GIAPPONE, e King of Prussia, Pennsylvania, USA – 6 aprile 2020 – Biotest, BPL, LFB e Octapharma si sono unite ad un’alleanza costituita da CSL Behring (ASX:CSL/USOTC:CSLLY) e Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) per lo sviluppo di una potenziale terapia di derivazione plasmatica per trattare la COVID-19. Questa alleanza partirà immediatamente con lo sviluppo sperimentale di una immunoglobulina iperimmune policlonale anti-SARS-CoV-2, senza denominazione commerciale, con la potenzialità di trattare individui con complicanze gravi da COVID-19.
“Situazioni mai viste prima richiedono mosse audaci” dice Julie Kim, Presidente della Business Unit Plasma-Derived Therapies di Takeda, “Noi tutti concordiamo che collaborando e mettendo insieme le risorse del settore possiamo accelerare l’immissione sul mercato di una potenziale terapia così come incrementarne la potenziale disponibilità. Invitiamo le aziende e le istituzioni che si occupano di plasma a supportare o a unirsi alla nostra alleanza”.
“I leader indicano la rotta durante i momenti di incertezza. Non c’è dubbio che tutti noi stiamo sperimentando l’impatto della COVID-19” dice Bill Mezzanotte, Executive Vice President e Responsabile della Ricerca e Sviluppo di CSL Behring. “Questo sforzo ha l’obiettivo di accelerare lo sviluppo di un’opzione terapeutica affidabile, percorribile e sostenibile che permetta ai sanitari di trattare i pazienti affetti dall'impatto di COVID-19. Oltre a mettere in comune le risorse delle aziende del settore, uniremo, ogni volta che potremo, i nostri sforzi a quelli governativi e accademici come un'unica alleanza, incluse attività importanti come gli studi clinici. Ciò renderà tutto più efficiente in questi tempi frenetici anche per queste parti interessate”.
La collaborazione sfrutterà le competenze ed il lavoro all'avanguardia che le aziende hanno già in corso. Gli esperti dell'alleanza inizieranno a collaborare su aspetti chiave quali raccolte di plasma, sviluppo di studi clinici e produzione. Anche altre aziende e istituzioni potranno aderire all'alleanza.
Lo sviluppo di un’immunoglobulina iperimmune richiederà la donazione di plasma da parte di molte persone che sono completamente guarite da COVID-19 e il cui sangue contiene anticorpi in grado di combattere il nuovo coronavirus. Una volta raccolto, il plasma "convalescente" verrebbe, quindi, trasportato negli impianti di produzione per essere sottoposto a trattamento certificato, inclusi efficaci processi di inattivazione e rimozione virale, e per venire purificato come prodotto finale.
Le persone interessate a donare plasma possono visitare questo link per trovare il centro di raccolta plasma autorizzato più vicino alla loro abitazione.
Circa Biotest AG
Biotest is a provider of plasma proteins and biological drugs. The corporate offices are located in Dreieich (near Frankfurt), Germany. With a value-added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. Biotest owns and operates 22 plasma donation centers across Europe in Germany, Hungary and Czech Republic. Biotest has more than 1,800 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. For more information visit http://www.biotest.com.
Circa Bio Products Laboratory (BPL)
Recognizing the power of plasma and with over 60 years heritage in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients and customers globally. Headquartered in the United Kingdom and with plasma collection centers across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com.
Circa CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 70 countries. For more information, visit www.cslbehring.com and for inspiring stories about the promise of biotechnology, visit Vita www.cslbehring.com/Vita.
LFB is a bio-pharmaceutical group that develops, manufactures and markets plasma derived products and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB was founded in 1994 in France and is among the leading European bio-pharmaceutical companies providing mainly hospital-based healthcare professionals, with blood-derived therapeutics with the vision to provide treatment options to patients in three major areas: immunology, haemostasis, and intensive care. LFB currently markets 15 products in more than 30 countries. www.groupe-lfb.com.
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Hematology; Immunotherapy and Critical care. Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 mil liters of plasma per annum. In addition, Octapharma operates more than 140 plasma donation centers across Europe and the US. For more information visit: www.octapharma.com
Circa Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit www.takeda.com.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding CSL Behring’s future business, future position and results of operations, including estimates, forecasts, targets and plans for CSL Behring. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on CSL Behring’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by CSL Behring or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding CSL Behring’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to CSL Behring’s operations and the timing of any such divestment(s), any of which may cause CSL Behring’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect CSL Behring’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in CSL Behring’s most recent Annual Report on Form 20-F and CSL Behring’s other reports filed with the U.S. Securities and Exchange Commission, available on CSL Behring’s website at: https://www.CSL Behring.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, achievements or financial position of CSL Behring could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. CSL Behring undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.
+61 412 635 483
+41 79 961 8464
+81 (0) 3-3278-2095